Food and Drug Administration

Dermatologic and Ophthalmic Drugs Advisory Committee

May 23, 2002

Briefing Information

BLA 125036, AMEVIVEŽ, alefacept  - indicated for the treatment of patients with chronic plaque psoriasis who are candidates for phototherapy or systemic therapy



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Biogen, Inc. - Briefing Document   pdf   doc

FDA - Briefing Document   pdf   doc

Errata   pdf   doc   htm